The Challenges and Economics of Drug Development in 2022
08 October 2012
Throughout its 50-year history, OHE has been a leader in contributing to the understanding of important trends in health care and in the life science industries, in the UK and outside. This conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development. Included are discussions about: why R&D and drug development processes are changing; how this will affect productivity; how collaboration and competition stimulate learning and commercialisation; and the changing roles of large and small biopharmaceutical companies, academia, governments, and payers. The conference will consider specific economic and regulatory incentives for encouraging drug development, including options for streamlining regulatory requirements, the appropriate use of health technology assessment, and incentives for R&D to meet global health challenges. The conference also will consider how to position the UK to retain and attract R&D.
Speakers and panelists include thought leaders in the sciences and health policy from the UK and elsewhere, the EMA, HTA agencies, life sciences companies, and academia.
Confirmed to date are:
- Professor Sir John Bell, Regius Professor of Medicine, Oxford University
- Professor Sir Alasdair Breckenridge, Chairman of the UK Medicines and Healthcare products Regulatory Agency (MHRA)
- Professor Patricia Danzon, Celia Moh Professor, Professor of Health Care Management, The Wharton School, University of Pennsylvania
- Dr Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
- Dr Rob Epstein, CEO and President of Epstein-French Associates
- Mr Robin Evers, Vice President, Worldwide Regulatory Strategy, Pfizer Ltd.
- Dr Sarah Garner, Associate Director for R&D/Project Director for Adaptive Licensing, Centre for Accelerating Medical Innovations, Oxford UniversityDr Jens Grueger, Head, Global Health Economics and Pricing, Roche Pharmaceuticals
- Dr Hannah Kettler, Senior Program Officer and Economist, Bill & Melinda Gates Foundation
- Professor Fabio Pammolli, Professor of Economics and Management, IMT Institute For Advanced Studies
- Dr Menelas Pangalos, Executive VP of Innovative Medicines, AstraZeneca
- Professor Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence (NICE)
- Professor Adrian Towse, Director, Office of Health Economics
When: 8 October 2012, 10.00 AM - 6.00 PM, followed by a drinks reception
Where: London Marriott Hotel County Hall, Westminster Bridge Road, London SE1
Please see the full programme for details.
Registration fees are as follows.
• £125 for government employees and full-time academics and students
• £195 for all others
10% discount for registrations received by 24 July 2012
Thank you for your interest. Registration now is closed.
Details about our registration policies are available here.